Atrix licenses Atrisorb GTR barrier to Block Drug; deal could generate $50 mil. in milestone payments.
This article was originally published in The Gray Sheet
Executive Summary
BLOCK DRUG TO MARKET ATRIX' ATRISORB GTR BARRIER IN U.S. and certain European markets under an agreement announced by the companies Dec. 17. The guided tissue regeneration barrier for the treatment of periodontal disease gained FDA approval in March. Atrix began selling the product in European markets during the first quarter of 1996; the firm commenced U.S. sales in July. The deal will put Atrisorb in the hands of Block's approximately 80 sales reps, who are expected to launch the product in the first quarter of 1997.
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.